Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. (December 2013)

• Record Type: Journal Article
• Authors: Scartozzi, Mario; Giampieri, Riccardo; Loretelli, Cristian; Bittoni, Alessandro; Mandolesi, Alessandra; Faloppi, Luca; Bianconi, Maristella; Prete, Michela Del; Andrikou, Kalliopi; Bearzi, Italo; Cascinu, Stefano
• Is Part Of: Pharmacogenomics. Volume 14:Number 16(2013)
• Page Start: 1991
• Page End: 1998
• Publication Date: 2013-12
• Subjects: cancer -- chemotherapy -- gastric -- genotype -- polymorphisms -- VEGF; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.185
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Besides correlating with prognosis, tumor-driven angiogenesis also seemed able to influence response/resistance to chemotherapy in preclinical models. We examined the role of tumor angiogenesis genotyping in determining clinical outcome in metastatic gastric cancer patients receiving first-line chemotherapy.Patients & methods: VEGF-A, VEGF-C, FLT1, KDR and FLT4 genotyping was analyzed in gastric tumors from patients receiving platinum-based first-line chemotherapy.Results: VEGF-A rs25648 correlated with response rate (partial response: 18% among patients showing the VEGF-A rs25648 CT or TT genotype vs 44% among patients showing the VEGF-A rs25648 C genotype; p = 0.04). At multivariate analysis only VEGF-A rs25648 maintained an independent role in determining median progression-free survival (hazard ratio: 1.65 95% CI: 1.12–2.78) and overall survival (hazard ratio: 1.58, 95% CI: 1.17–2.65).Conclusion: VEGF-A rs25648 genotyping may help identify a patient subgroup unlikely to benefit from a first-line, platinum-based combination and potential candidates for alternative therapy choices. Original submitted 26 July 2013; Revision submitted 16 September 2013; Published online 3 October 2013